Headquartered in Cambridge, MA·Fiscal year ends December·NASDAQ: EDIT·editasmedicine.com
About Editas Medicine
Editas Medicine is a clinical-stage gene editing company that uses CRISPR genome editing systems to develop durable, precision in vivo medicines for serious diseases. Its lead candidate, EDIT-401, is an experimental in vivo therapy for hyperlipidemia. It uses an upregulation approach that edits the LDLR gene to increase LDLR protein expression and lower LDL-C. EDIT-401 is entering the Phase 1/2 Strive study in patients with Heterozygous Familial Hypercholesterolemia in Australia. The company is also developing a targeted lipid nanoparticle (tLNP) platform for extrahepatic delivery, including in vivo delivery of mRNA to T-cells. Editas is the exclusive licensee of the Broad Institute's Cas12a patent estate and of the Broad Institute and Harvard University Cas9 patent estates for human medicines. It earns collaboration and other R&D revenue from partnerships and licensing, including milestones from its Bristol Myers Squibb collaboration. Under that collaboration, BMS is developing alpha-beta T cell medicines such as BMS-986527, a CD70 healthy-donor allogeneic CAR-T therapy engineered with Editas' Cas12a technology. Updated
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would…
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
There has been a noticeable shift in the stock market over the last two months. Investors are moving away from former high-flying large- and mega-cap stocks into discounted small-cap names that the…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto Networks.
Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne, Trade Desk, Valvoline and Walmart.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, American Eagle Outfitters, Azek, Bausch Health, Coinbase Global, Dell Technologies, Fidelity National Information Services, Invesco, Marathon Petroleum, Netflix, New Residential Investment, Spotify…
Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont and Salesforce.com.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Caesars Entertainment, Coinbase Global, Editas Medicine and Wynn Resorts.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including Bath & Body Works, Editas Medicine, GoDaddy, PetMed Express and Qorvo.
Editas Medicine is a clinical-stage gene editing company that uses CRISPR genome editing systems to develop durable, precision in vivo medicines for serious diseases. Its lead candidate, EDIT-401, is an experimental in vivo therapy for hyperlipidemia.
What is the EDIT stock price target?
The Wall Street consensus 12-month price target for EDIT is $6.10.